Femasys (FEMY) — Commercial relationships that drive the women’s-health playbook

Femasys is a medical-device company that sells minimally invasive women's-health products (notably FemaSeed and FemVue) directly to U.S. clinics and to international distributors, monetizing through product sales recognized at shipment and standard 30–60 day payment terms. The company’s revenue model is highly concentrated on clinical customers and a small number of distributor partners, and growth is being driven by selective clinic rollouts and targeted distributor agreements in Europe. For a concise view of partner relationships and commercial risk, see more at https://nullexposure.com/.

How Femasys actually makes money and how it contracts with customers

Femasys generates revenue primarily from single-sale product transactions: reproductive endocrinologists and gynecological clinics purchase FemaSeed and FemVue; international sales flow through distribution partners. The company recognizes revenue when control transfers to the buyer — upon shipment or delivery depending on shipping terms — which is consistent with spot-sale economics and short receivable cycles. Financial disclosures indicate payment terms and control transfer mechanics that produce transactional, not subscription, revenue.

Several company-level signals shape commercial risk and opportunity:

• Concentration risk: Two customers represented 15% and 12% of 2024 revenue, which signals that large buyers materially affect near-term top-line performance.
• North America-first commercialization: Management is focusing direct sales in North America while using distributors for international markets, which concentrates execution risk in its domestic commercial team.
• Active commercialization of core products: FemaSeed and FemVue are the primary revenue drivers and are currently being commercialized in the U.S. and select international markets.
• Contracting posture is transactional: Contract excerpts reflect spot, shipment-based transfers of control and EX‑Works shipping for distributors, consistent with one‑off product sales rather than long-term, captive contracts.

These characteristics create a business with high operational leverage to new clinic rollouts and distributor wins, but also material customer concentration and geographic skew that investors must track closely. Learn more about counterparty exposure at https://nullexposure.com/.

Customer relationships that matter — what public sources show

Below are the customer and distribution relationships surfaced in public reports and press releases; each entry includes a one- to two-sentence summary and the source.

Kebomed / Kebomed Europe AG (France and Benelux)

Femasys announced a partnership to commercialize FemBloc in France and the Benelux region, and reported an initial order of approximately $500,000 USD supporting the commercial launch in those markets. According to a Yahoo Finance release (Mar 9, 2026) and a GlobeNewswire financial update (Nov 14, 2025), Kebomed is the appointed European distributor for these territories.

Refuah Health Center

Femasys entered a clinic partnership with Refuah Health Center to offer FemaSeed as a first-line infertility treatment option in community-based care settings. This arrangement was described in a Jan 13, 2026 press release distributed via Sahm Capital and subsequently reported on Quiver Quant (Jan 2026), positioning Refuah as an early channel partner for expanding access.

Carolinas Fertility Institute

Femasys announced a U.S. clinic partnership with Carolinas Fertility Institute to roll out FemaSeed across eight locations, embedding the product directly into a multi-site fertility practice network. Industry coverage (TS2 Tech, 2025) referenced this eight-site rollout as part of the company’s initial U.S. commercialization activity.

What these relationships imply for revenue quality and growth

The mix of clinic partnerships and distributor agreements highlights a deliberate go-to-market split: direct clinical adoption in North America to establish clinical evidence and usage patterns, paired with distribution deals to scale internationally. The Kebomed engagement is strategic for France and Benelux distribution and delivers tangible near-term revenue (the $500k order). Clinic partnerships like Refuah and Carolinas Fertility Institute are critical for on‑the‑ground adoption and repeat procedure volume.

Key commercial takeaways:

• Revenue is transactional and lumpy. Spot shipments and distributor orders produce uneven revenue timing tied to device orders rather than recurring billing.
• Concentration is material. The company reported that two customers exceeded 10% of revenue in 2024, which amplifies downside if a major account reduces orders.
• International scale depends on distributors. EX‑Works and other shipping terms place responsibility for market execution on distribution partners once products leave Femasys’ facility.
• Clinical rollouts validate longer-term demand. Multi-site clinic arrangements are the vehicle for converting clinical adoption into repeat purchases.

If you want ongoing coverage of partner-level risk and revenue implication, visit https://nullexposure.com/ for deeper counterparty analysis.

Risk factors investors should weigh now

• Customer concentration: Two customers accounted for a material share of 2024 revenue; a loss or slow ordering cadence from one would materially affect reported top line.
• Spot sale economics: Revenue recognized at shipment makes quarterly results dependent on timing of orders and inventory shipments, increasing reported volatility.
• Geographic execution risk: The business concentrates direct selling in North America and relies on distributors overseas; international growth will depend on distributor performance and regulatory pathways in each market.
• Early commercial stage: Product commercialization is active but still recent; scaling from pilot clinic rollouts to broad adoption will determine whether current partner wins translate to sustained revenue growth.

Bottom line — where partner wins matter most

Femasys’ current commercial architecture is simple and outcome-driven: clinic partnerships to create clinical traction, and select distributor deals to scale internationally. The Kebomed order and clinic rollouts with Refuah and Carolinas Fertility Institute are the kinds of wins that move revenue in a company with concentrated, transactional sales. Investors should treat short-term performance as highly sensitive to order timing and a small pool of large purchasers, while monitoring whether clinic adoption converts to repeat, routine purchasing.

For a focused counterparty and customer-exposure briefing tailored to investment due diligence, see our platform at https://nullexposure.com/.